Ottawa, ON – The Canadian Radiation Oncology Foundation and sanofi-aventis have announced the creation of a new award for colorectal or prostate cancer research.
The Canadian Radiation Oncology Foundation/Sanofi-Aventis Research Innovation Award (CASARIA) will make available $140,000 in grants for research focusing on colorectal or prostate cancer. Proposals will be reviewed and recommended for funding on the basis of scientific merit, feasibility and relevance to Canadian radiation oncology.
“By promoting innovative research into new anticancer medicines and targeted radiation therapy, this award will offer considerable long-term benefits to patients with rectal and prostate cancers,” said Matthew B Parliament, MD, FRCPC, and president of the Canadian Association of Radiation Oncology (CARO). “We want to express our thanks to sanofi-aventis for encouraging the studies that aim to improve prospects for cure and quality of life for the thousands of patients diagnosed with these cancers every year.”
The CASARIA competition is open to both clinical and non-clinical projects. Applications should be submitted online, using the CASARIA document template link (http://www.caro-acro.ca/Links/CROF.htm) to the CROF head office by April 12, 2010. Successful proposals will be announced in May 2010.